Research programme: B-cell isolation platform therapeutics - Adimab

Drug Profile

Research programme: B-cell isolation platform therapeutics - Adimab

Alternative Names: Anti-Ebola virus antibodies - Adimab; Anti-RSV antibodies

Latest Information Update: 16 Dec 2016

Price : $50

At a glance

  • Originator Adimab
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Respiratory syncytial virus infections

Highest Development Phases

  • Preclinical Ebola virus infections
  • Research Respiratory syncytial virus infections

Most Recent Events

  • 09 Dec 2016 Research programme: B-cell isolation platform therapeutics - Adimab is available for licensing as of 09 Dec 2016.
  • 18 Feb 2016 Early research in Respiratory syncytial virus infections in USA (Parenteral) before February 2016
  • 18 Feb 2016 Preclinical trials in Ebola virus infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top